Comparative Pharmacology
Head-to-head clinical analysis: EGATEN versus PROTOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EGATEN versus PROTOSTAT.
EGATEN vs PROTOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triclabendazole inhibits tubulin polymerization by binding to the colchicine binding site on beta-tubulin, leading to disruption of microtubule formation and paralysis/death of susceptible parasites, particularly Fasciola species.
Proto-oncogene tyrosine-protein kinase Src inhibitor; inhibits cell proliferation and induces apoptosis in cancer cells overexpressing Src.
10 mg/kg orally as a single dose, with food; for fascioliasis, 10 mg/kg orally three times daily for 3 days.
250 mg orally three times daily after meals for 7-10 days; alternatively, 500 mg twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 8-12 hours in severe hepatic impairment. Clinical context: supports once-daily dosing.
8 hours (range 6-10 h); in renal impairment, half-life prolonged up to 20 hours; dose adjustment required for CrCl < 30 mL/min.
Primarily fecal (90% as metabolites); renal excretion of unchanged drug is negligible (<1%).
Renal: 70% as unchanged drug; biliary/fecal: 15% as metabolites; 15% other.
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent